Objective:
This research aimed to screen the prevalence of lymphadenopathy following COVID-19 vaccination in Saudi Arabia.
Methods:
This cross-sectional study was conducted through an online survey among residents of Saudi Arabia who received the COVID-19 vaccine. The study was conducted from November, 2021 to August, 2022.
Result:
Total 500 participants’ responses were evaluated. There were 360 (72%) women and 140 (28%) men. After receiving the COVID-19 vaccination, 71 participants (14.2%) reported having lymphadenopathy. Participants with lymphadenopathy were younger than those without lymphadenopathy (19-28 years), females (80.3%) but without a significant relationship. Lymphadenopathy showed more association with Pfizer-BioNTech vaccine. Fifty-three participants (74.7%) reported lymphadenopathy on the same side of the vaccine injection and participants who received three doses of the vaccine had a significant higher percentage of having painful lymphadenopathy
Conclusion:
Lymphadenopathy is considered one of the most common side effects of vaccination after COVID-19.
Key words: vaccination, pfizer-biontech, oxford-astrazeneca, moderna, vaccine, covid-19, lymphadenopathy.
|
